Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Xbrane Biopharma AB ( (SE:XBRANE) ).
Xbrane Biopharma AB has issued 420,517 warrants to Fenja Capital II A/S as part of a conditional financing solution linked to a SEK 60 million loan agreement. This move follows a delay in the US FDA approval of Lucamzi, a proposed biosimilar for Lucentis. The issuance of warrants is a strategic step to address short-term financing needs and reflects market conditions after negotiations with Fenja Capital. The decision will result in a 2% dilution of shares if all warrants are exercised.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK8.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB develops biological drugs using a patented platform technology that reduces production costs compared to competitors. The company focuses on biosimilar candidates with a market potential of EUR 23 billion in estimated annual peak sales. Xbrane’s lead product, Ximluci®, has received market authorization in Europe and was launched in 2023. The company is headquartered in Solna, Sweden, and is listed on Nasdaq Stockholm.
YTD Price Performance: -56.64%
Average Trading Volume: 171,897
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK179.6M
See more insights into XBRANE stock on TipRanks’ Stock Analysis page.